Cargando…
Biotherapies in Solid Tumors: Are Negative Results Still of Low Priority for Publication?
In 2005, we performed the largest survey on clinical trials of biotherapies for all solid tumors and found indirect evidence of a publication bias: editors of medical journals were more prone to publish positive results independently from the quality of the studies. We collected data from 2003 to 20...
Autores principales: | Ottaiano, Alessandro, Cassata, Antonino, Capozzi, Monica, De Divitiis, Chiara, De Stefano, Alfonso, Avallone, Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861183/ https://www.ncbi.nlm.nih.gov/pubmed/29594042 http://dx.doi.org/10.3389/fonc.2018.00062 |
Ejemplares similares
-
Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice
por: Ottaiano, Alessandro, et al.
Publicado: (2019) -
First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis
por: Ottaiano, Alessandro, et al.
Publicado: (2018) -
Integration of stereotactic radiotherapy in the treatment of metastatic colorectal cancer patients: a real practice study with long-term outcome and prognostic factors
por: Ottaiano, Alessandro, et al.
Publicado: (2018) -
Funds Reimbursement of High-Cost Drugs in Gastrointestinal Oncology: An Italian Real Practice 1 Year Experience at the National Cancer Institute of Naples
por: Capozzi, Monica, et al.
Publicado: (2018) -
Bevacizumab-Induced Tumor Vasculature Normalization and Sequential Chemotherapy in Colorectal Cancer: An Interesting and Still Open Question
por: Ottaiano, Alessandro, et al.
Publicado: (2021)